Analyst firms · Morgan Stanley · BNTX

Morgan Stanley BNTX price target and rating history

BioNTech SE (BNTX) · Health Care

Morgan Stanley rates BioNTech SE (BNTX) Overweight with a $145 price target, as of its latest action on Sep 24, 2024. It has published 4 rating actions on BNTX since December 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a BNTX price target in the last 12 months, the median target is $113.

Current rating
Overweight
Price target
$145
Median target, all firms
$113
Actions on BNTX
4

Morgan Stanley price target on BNTX

$294$220$14520222023202420252026
Morgan Stanley price target on BNTX, each point a stated target, December 2021 to September 2024.

Every Morgan Stanley rating on BNTX

How other firms rate BNTX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchHoldOct 8, 2026
BMO Capital MarketsMarket Perform$105Sep 8, 2026
UBSBuy$135May 27, 2026
BernsteinMkt Perform$96May 22, 2026
Leerink PartnersMarket Perform$113Feb 2, 2026
Goldman SachsBuy$142Jan 16, 2026

Questions about Morgan Stanley and BNTX

What is Morgan Stanley's price target for BNTX?
Morgan Stanley's latest stated price target for BioNTech SE (BNTX) is $145, from its action on Sep 24, 2024.
What is Morgan Stanley's rating on BNTX?
Morgan Stanley rates BNTX Overweight, a bullish rating, as of Sep 24, 2024.
When did Morgan Stanley last change its view on BNTX?
On Sep 24, 2024, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $93 to $145.
How does Morgan Stanley's BNTX target compare with other analysts?
Across 5 firms with a BNTX price target in the last 12 months, the median target is $113.

More BNTX rating histories

All Morgan Stanley ratingsBNTX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.